Novo Nordisk CEO Rules Out Transformative M&A for Current Strategy

Novo Nordisk CEO Maziar Mike Doustdar announced during a second-quarter earnings call that the company is not currently positioned to pursue large-scale, transformative mergers and acquisitions. Instead, the company will focus on bolt-on acquisitions designed to complement its internal research and development pipeline.

This cautious approach follows a series of setbacks, including the company's failure to acquire Metsera and disappointing clinical outcomes. The cardiovascular drug ziltivekimab failed its Phase III trial, and CagriSema underperformed in comparison to Eli Lilly's tirzepatide. These challenges persist despite Novo Nordisk reporting a 7% increase in adjusted sales for the second quarter and sustained volume growth for its GLP-1 receptor agonists.

The strategic shift occurs as Novo Nordisk continues to struggle against the market dominance of Eli Lilly and Company in the obesity and type 2 diabetes segments. While the company remains open to future large-scale deals if circumstances change, the current priority is augmenting internal R&D through smaller, targeted assets.